Albany Molecular Research, Inc.

Affinium Pharmaceuticals, Inc.

Bristol-myers Squibb Compnay

Warner-lambert Company

Smiths Detection Inc.

Debiopharm International, S.a.

David Douglas Manning

Peter Guzzo

Zhicai Yang

Bruce Francis Molino

Richard Eric Olson

Shuang Liu

Christopher Cioffi

Matthew L Isherwood

Wenge Cui

Kassoum Nacro

Aruna Sambandam

Min Hu

Congxiang Zha

Peter Brent Sampson

Matthew Surman

Jailall Ramnauth

Judd Berman

Helene Decornez

William Earley

Kristen N Fleming

Jun-Ho Maeng

John R Laverack

Heinz W Pauls

Greg G Weaver

George Edward Riehm

Sham Shridhar Nikam

Ian Leslie Scott

Peter C Michels

Brian Edward Kornberg

Andras Toro

Russell Andrew Lewthwaite

Cheng Guo

Henry Pauls

Kristen N Ryan

Kenneth C Schreiber

Bruce J Sargent

Kenneth J Fredeen

Dejian Xie

Fernando J Martin

Matthew W Chase

Grant J Carr

Peter R Guzzo

Judd M Berman

Helene Yvonne Decornez

Christopher L Cioffi

Bruce Jeremy Sargent

Fernando J L Martin

Provided herein are improved solid phase micro-extraction (SPME) devices, systems comprising such devices, and methods of use and manufacture thereof. In particular, SPME devices provided herein are configured to prevent damage (e.g., to the device and/or to a system in which they are employed) incurred, for example, through user error.

Solid phase micro-extraction (SPME) devices

The compounds of the present invention are represented by the following aryl- and heteroaryl-substituted tetrahydrobenzazepine and dihydrobenzazapine derivatives having formulae I(A-E) and formula (II): where the carbon atom designated * is in the R or S configuration, and the substituents X and R-Rare as defined herein.

Aryl- and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin

The present invention relates to ligand-therapeutic agent conjugate compounds, silicon linkers for the conjugate compounds, compositions, methods for making them, and methods for the treatment of cancer using the conjugate compounds. The silicon-based linkers described herein can be used to deliver desired therapeutic agents to particular cells or tissue types targeted by the ligand.

Ligand-therapeutic agent conjugates, silicon-based linkers, and methods for making and using them

Novel 5-HTreceptor modulators are disclosed. These compounds are used in the treatment of various disorders, including chemotherapy-induced nausea and vomiting, post-operative nausea and vomiting, and irritable bowel syndrome. Methods of making these compounds are also described in the present invention.

5-HT3 receptor modulators, methods of making, and use thereof

The present invention relates to novel therapeutics with antibacterial activity, processes for their preparation, and pharmaceutical, veterinary and nutritional compositions containing them as active ingredients. The present invention also relates to uses of the novel therapeutics, for example, as medicants or food additives in the treatment of bacterial infections or to aid body mass gain in a subject.

Antibacterial compounds, methods of making them, and uses thereof

[object Object]

In part, the present invention is directed to antibacterial compounds.

Therapeutic agents, and methods of making and using the same

Compounds of formulae I and II: are disclosed as 5-HTinhibitors. Those compounds are useful in treating CINV, IBS-D and other diseases and conditions.

2-alkylbenzoxazole carboxamides as 5HT3 modulators

The compounds of the present invention are represented by the following aryl- and heteroaryl-substituted tetrahydrobenzazepine and dihydrobenzazapine derivatives having formulae I(A-E) and formula (II):  where the carbon atom designated * is in the R or S configuration, and the substituents X and R-Rare as defined herein.

Compounds of formulae I, II and III: are disclosed as 5-HT3 inhibitors. The compounds are useful in treating CINV, IBS-D and other diseases and conditions.

2-aminobenzoxazole carboxamides as 5HT3 modulators

The present invention relates to a process for preparation of a trans ISA247 compound of the formula: where R&#x2550;H or D; R&#x2550;H or D; and R&#x2550;H or D, by application of organozirconium chemistry. The process involves reacting an acetyl cyclosporin aldehyde with an organozirconium reagent to provide acetyl cyclosporin diene (the acetate of trans ISA247) and deacetylating the acetyl cyclosporin diene to produce the trans-isomer of ISA247. The present invention also relates to a process for preparing the same trans ISA247 compound, using olefin cross metathesis. The process involves: olefin cross metathesis of acetyl cyclosporin A to afford acetyl cyclosporin &#x3b1;,&#x3b2;-unsaturated aldehyde; Wittig reaction of the acetyl cyclosporin &#x3b1;,&#x3b2;-unsaturated aldehyde to provide acetyl cyclosporin diene; and deacetylation of the acetyl cyclosporin diene to produce the trans ISA247 compound. Also disclosed are processes for preparing an acetyl cyclosporin &#x3b1;,&#x3b2;-unsaturated aldehyde compound and a cyclosporin triene analogue compound. 

Growing community of inventors

Duanesburg, NY, United States of America

David Douglas Manning